In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

As per Vantage Market Research, the Pharmaceutical Manufacturing Market is poised for growth due to various factors, such as ...

If you’re on the fence about investing in Ionis Pharmaceuticals, Inc., Neurocrine Biosciences ... and collaboration and ...

Empty capsules offer a fast, effective, and patient-friendly way to deliver both pharmaceutical and nutraceutical substances. Unlike other dosage forms, capsules are easy to swallow and less likely to ...

With a market projected to reach US$ 2,301.6 billion by 2032, the pharmaceutical manufacturing industry is not just growing—it’s evolving. The convergence of digital innovation, changing disease ...

shortly after the FDA’s back-to-back approvals for GSK’s RSV shot Arexvy and Pfizer’s rival product Abrysvo. The British pharma claimed that the Pfizer vaccine infringed on four of its ...

April 3 (Reuters) - British pharmaceutical giant GlaxoSmithKline (GSK.L), opens new tab and rival Pfizer (PFE.N), opens new tab have agreed to end a lawsuit that alleged Pfizer's respiratory ...

FTSE 100 pharmaceutical giants GSK and Astrazeneca may have avoided the brunt of US President Donald Trump's tariffs, a City broker suggests. Pharmaceutical goods seem to be exempt from the ...

GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification ...

GlaxoSmithKline’s new chief executive Emma Walmsley has unveiled her strategy for the company, saying its pharma division must focus more on its key assets and deliver ‘full value’ from ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

ATC Energies System's SME IPO was fully subscribed 1.32 times, raising Rs 63.76 crore. Shares will list on NSE SME with a 6% premium over issue price.